5-hydroxytryptamine inhibits the tachycardia induced by selective preganglionic sympathetic stimulation in pithed rats

Life Sciences

Volumn 64, Issue 20, 1999, Pages 1839-1847

  Villalón, Carlos M ^a   Centurión, David ^a   Del Mar Fernández, María ^b   Morán, Asunción ^b   Sánchez López, Araceli ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

5 hydroxytryptamine; Prejunctional inhibition; Sympathetic outflow; Tachycardia

Indexed keywords

DESIPRAMINE; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR AUTOREGULATION; CONTROLLED STUDY; MALE; NONHUMAN; PREGANGLIONIC NERVE CELL; RAT; SPINAL ANIMAL; SYMPATHETIC NERVE CELL; SYMPATHETIC TONE; TACHYCARDIA;

ANIMALS; AUTONOMIC FIBERS, PREGANGLIONIC; DECEREBRATE STATE; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ELECTRIC STIMULATION; HEART RATE; INFUSIONS, INTRAVENOUS; MALE; NOREPINEPHRINE; RATS; RATS, WISTAR; SEROTONIN; SYMPATHETIC NERVOUS SYSTEM; TACHYCARDIA; VAGOTOMY;

ANIMALIA;

EID: 0033537863     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(99)00126-5     Document Type: Article

References (26)

1. P. Saxena and C. Villalón, J. Cardiovasc. Pharmac. 15 (Suppl. 7) S17-S34 (1990).
2. P. Saxena and C. Villalón, Trends Pharmac. Sci. 12 223-227 (1991).
3. C. Villalón, P. De Vries, and P. Saxena, Drug Disc. Today 2 294-300 (1997).
4. P. Saxena, P. De Vries and C. Villalón, Trends Pharmac. Sci. 19 311-316 (1998).
5. P. Humphrey, W. Feniuk, M.J. Perren, H.E. Connor, A.W. Oxford, I.H. Coates and D. Butina, Br. J. Pharmac. 94 1123-1132 (1988).
6. M. Göthert, K. Fink, G.J. Molderings and E. Schlicker, Cardiovascular Pharmacology of 5-HT. Prospective Therapeutic Applications, P.R. Saxena. D. Wallis, W. Wouters and P. Bevan (Eds), 285-294, Kluwer Academic Publishers, Dordrecht (1990).
7. R.A. Cohen, J. Pharmac. Exp. Ther. 235 76-80 (1985).
8. C. Villalón, J.A. Terrón and E. Hong, Eur. J. Pharmac. 240 9-20 (1993).
9. C. Villalón and J.A. Terrón, Br. J. Pharmac. 113 13-20 (1994).
10. W. Feniuk, P. Humphrey and A.D. Watts, J. Auton. Pharmac. 1 127-132 (1981).
11. G.J. Molderings, M. Göthert, K. Fink, E. Roth and E. Schlicker, Eur. J. Pharmac. 164 213-222 (1989).
12. K.G. Charlton, B.A. Bond and D.E. Clarke, Naunyn-Schmiedeberg's Arch. Pharmac. 332 8-15 (1986).
13. G.J. Molderings, K. Fink, E. Schlicker and M. Göthert, Naunyn-Schmiedeberg's Arch. Pharmac. 336 245-250 (1987).
14. C. Villalón, J. Contreras, E. Ramírez-San Juan, C. Castillo, M. Perusquía, F.J. López-Muñoz and J.A. Terrón, Life Sci. 57 803-812 (1995).
15. C. Villalón, J. Contreras, E. Ramírez-San Juan, C. Castillo, M. Perusquia and J.A Terrón, Br. J. Pharmac. 116 3330-3336 (1995).
16. C. Villalón, D. Centurión, G. Rabelo, P. De Vries, P.R. Saxena and A. Sánchez-López, Br. J. Pharmac. 124 1001-1011 (1998).
17. J.R. Docherty, Naunyn-Schmiedeberg's Arch. Pharmac. 337 1-8 (1988).
18. M. Göthert, E. Schlicker and P. Kollecker, Naunyn-Schmiedeberg's Arch. Pharmac. 332 124-130 (1986).
19. M.K. Krstic and Z.S. Katusic, Eur. J. Pharmac. 85 225-227 (1982).
20. J.S. Gillespie, A. Maclaren and D. Pollock, Br. J. Pharmac. 40 257-267 (1970).
21. R.G.D. Steel and J.H. Torrie, Principles and Procedures of Statistics. A Biomedical Approach, McGraw Hill Inc., New York (1985).
22. S.J. Ireland and C.C. Jordan, Br. J. Pharmac. 92 417-427 (1987).
23. J.F.X. Jones, G.R. Martin, and A.G. Ramage, Br. J. Pharmac. 116 1715-1717 (1995).
24. S.Z. Langer, Pharmac. Rev. 32 337-362 (1980).
25. S.Z. Langer, Trends Pharmac. Sci. 18 95-99 (1997).
26. M.J. Rand, H. Majewski, H. Wong-Dusting, D.F. Story, R.E. Loiacono and J. Ziogas, J. Cardiovasc. Pharmac. 10 (Suppl. 12) S33-S44 (1987).